Custom Peptide Synthesis Feasibility Review

Read the sequence as a process

Length increases accumulated coupling risk. Hydrophobic stretches and β-sheet-prone motifs encourage on-resin aggregation, slowing deprotection and coupling. Repeated or adjacent prolines can introduce sequence-specific side reactions. Asp-Gly and related motifs may raise aspartimide concerns depending on protection and conditions. Methionine, tryptophan, and cysteine need oxidation control.

Calculate net charge and pI, but include terminal state and noncanonical modifications. A neutral, hydrophobic sequence may be difficult to handle in both synthesis and purification. A highly charged peptide may be soluble yet retain poorly on standard RP-HPLC.

Flow-SPPS research shows that deprotection traces can reveal sequence-dependent aggregation and difficult coupling. A conventional synthesis team can still use small-scale scouting, resin tests, repeat-coupling records, and crude LC-MS to locate risk.

Modifications change the project

Lipidation, PEGylation, fluorophores, biotin, chelators, phosphates, glycosylation, and multiple disulfides are separate synthetic operations. Attachment site, linker, protecting-group compatibility, regioselectivity, and purification behavior must be specified.

A fluorescent label can dominate UV detection and hydrophobic retention. A lipid chain can cause adsorption and carryover. A metal-binding peptide may require metal-free processing. A disulfide-rich peptide needs an oxidation strategy and connectivity mapping, not only intact mass.

Clarify whether the customer wants free peptide, TFA, acetate, chloride, or another salt. Counterion exchange changes yield, water, and content. “10 mg peptide” must state whether it means gross salt mass or net peptide content.

Questions before the quotation

• Exact sequence, termini, stereochemistry, noncanonical residues, and modifications.
• Required scale on gross weight or net peptide-content basis.
• Purity target, specified impurities, counterion, water, and formulation.
• Analytical package: HPLC, intact MS, peptide map, disulfide map, amino-acid analysis, or bioassay.
• Intended RUO matrix, concentration, solubility, packaging, and shipping condition.
• Acceptance of staged feasibility work and alternative design options.

Quote uncertainty honestly

For high-risk sequences, offer a small-scale feasibility batch before committing to final scale. Report crude purity, major impurity families, purification recovery, solubility, and expected isolated yield. A guaranteed 98% purity says nothing about whether enough material can be recovered.

Purity and yield trade against each other. Repeated preparative chromatography may deliver a tiny 99% fraction while discarding most peptide. If the research only needs 90–95% with full impurity documentation, a different control strategy may be more useful.

Alternative sequences, solubilizing tags, pseudoproline building blocks, backbone protection, different resin loading, or fragment condensation can reduce risk. Design changes must be approved before synthesis and recorded as a different molecule.

Supplier screening

Ask for examples of comparable length, hydrophobicity, and modification—not an unrelated easy peptide. Review crude and final data, yield basis, scale-up plan, and subcontracted work. A broker may be capable of coordination but should disclose the manufacturing site.

Define what happens after failure. Re-synthesis, method redevelopment, partial delivery, and refund terms belong in the order. Keep sequence confidentiality and intellectual-property handling explicit.

Purification feasibility is often the limiting step

Predict where the target and likely deletion, oxidation, or truncation impurities will elute. If they are nearly isobaric and coeluting, a nominal 98% target may require orthogonal purification or a redesigned synthesis. Preparative loading that works at milligram scale may lose resolution during scale-up.

Ask what yield is measured: crude peptide on resin, recovered purified peptide, lyophilized salt, or net peptide content. These numbers are not interchangeable. A quotation promising 100 mg can deliver much less active peptide when water and TFA are considered.

For very hydrophobic sequences, purification solvent and final isolation can become the bottleneck. Material may remain soluble in high organic content then precipitate during pooling, exchange, or drying. Require a recovery study across the whole workflow, not only a clean analytical fraction.

Define QC before synthesis

An HPLC percentage and one intact mass may be adequate for exploratory work but insufficient for a disulfide-rich, lipidated, or positional-modification project. List identity depth, impurity reporting threshold, peptide content, water, counterion, residual solvent, and packaging before pricing.

For isotopically labeled peptides, define isotope incorporation and isotopic purity separately from chemical purity. For phosphopeptides, confirm site and monitor dephosphorylation. For cyclic peptides, specify ring closure and exclude linear precursor. For branched or conjugated constructs, intact mass alone may not prove attachment position.

Bioactivity testing requires a qualified assay and reference; it should not be added as a vague “activity confirmed” line. If the supplier cannot support it, keep structural qualification separate and let the research laboratory perform the functional comparison.

Scale-up and change control

A successful 5 mg feasibility run does not guarantee a 500 mg process. Resin mixing, heat transfer, reagent equivalents, preparative loading, and drying behavior change. Agree on scale-up checkpoints and acceptance before consuming the entire project budget.

Require approval for sequence, protecting group, resin, coupling reagent, counterion, or analytical-method changes. A supplier may make a sensible process improvement, but the customer must know whether the delivered material remains comparable to the feasibility batch.

Preserve crude and purified retains. If a later assay fails, crude data can distinguish synthesis error from purification enrichment or storage degradation. Without retains, both sides argue from final PDFs.

Peptides Archive can help research teams prepare an RUO synthesis RFQ or review feasibility risks before supplier selection. No medical or human-use guidance is provided.

Primary records and verification routes

Use the primary paper, current regulator record, or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not evidence itself.